Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:18:18.464Z.
Calculation as of: 2026-10-06T16:18:18.464Z.
Quote observation: 2026-10-06T16:14:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4553d85706fed5bac33927ddb0c45062b9ca990621471d16f8faa1ad8920ffc8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$163.00M
EBITDA Yield
N/A
TTM Avg
12.03%
3Y Avg
9.31%
5Y Avg
9.31%
Market Cap
$159.33M
EBITDA Yield
N/A
TTM Avg
38.61%
3Y Avg
38.61%
5Y Avg
38.61%
Market Cap
$169.85M
EBITDA Yield
0.47%
TTM Avg
9.63%
3Y Avg
6.71%
5Y Avg
7.90%
Market Cap
$162.60M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PepGen Inc. (PEPG) | $162.89M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $163.00M | N/A | 12.03% | 9.31% | 9.31% |
| Quanterix Corporation (QTRX)vs › | $164.16M | N/A | N/A | N/A | N/A |
| OptimizeRx Corp. (OPRX)vs › | $165.58M | 9.59% | 9.66% | 8.38% | 4.23% |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.33M | N/A | 38.61% | 38.61% | 38.61% |
| Inogen, Inc. (INGN)vs › | $157.57M | N/A | 4.75% | 3.30% | 2.87% |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.85M | 0.47% | 9.63% | 6.71% | 7.90% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $162.60M | N/A | N/A | N/A | N/A |
| MediWound Ltd. (MDWD)vs › | $170.85M | N/A | 16.58% | 16.58% | 16.58% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $153.40M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
